William A. Garvin, shareholder in Buchanan’s FDA & Pharmaceuticals practice, was quoted in a Bloomberg Law article titled, “FDA Delays Lab Test Changes Until Trump Takes Office.

“Given the fact that people are uncertain about what the new administration is going to do with regards to certain FDA regulatory positions and priorities, the FDA is trying its best to hold off on taking positions that would need to get revised once Trump is in office,” Garvin said.